中国经济网北京12月4日讯 11月28日，深圳证券交易所、深圳证券信息有限公司发布《关于调整深 证成指、创业板指、深证100、创业板50等指数样本股的公告》。根据指数编制规则，深圳证券交易所 和深圳证券信息有限公司决定于2025年12月15日对深证成指、创业板指、深证100、创业板50等指数实 施样本股定期调整。 资料显示，姚小青于2022年4月22日至2024年4月1日任公司董事长。截至2024年9月30日，姚小青持 有红日药业10.24%股份，为第二大股东。 姚小青，中国国籍，拥有澳大利亚五年期居留权，男，1965年5月生，博士，执业医师、正高级工 程师。1996年创办天津红日药业股份有限公司，2022年4月22日至2024年4月1日任公司董事长。 据新浪财经信息，数据显示，姚小青最初持股8646.25万股，占总股本的23.12%。姚小青从2013年7 月2日起，第一次减持红日药业股份，迄今为止，累计减持公司股票1.17亿股，累计套现约8.51亿元。 （责任编辑：华青剑） 红日药业（300026）被调出深证成份指数样本股名单。 | | 调入名单 | | 调出名单 | | --- | --- | --- | ...

中国经济网北京12月4日讯11月28日，深圳证券交易所、深圳证券信息有限公司发布《关于调整深证成 指、创业板指、深证100、创业板50等指数样本股的公告》。根据指数编制规则，深圳证券交易所和深 圳证券信息有限公司决定于2025年12月15日对深证成指、创业板指、深证100、创业板50等指数实施样 本股定期调整。 红日药业（300026）被调出深证成份指数样本股名单。 姚小青，中国国籍，拥有澳大利亚五年期居留权，男，1965年5月生，博士，执业医师、正高级工程 师。1996年创办天津红日药业股份有限公司，2022年4月22日至2024年4月1日任公司董事长。 红日药业11月6日晚间披露《关于持股5%以上的股东、公司部分高级管理人员减持股份预披露公告》。 根据公告，持股5%以上的股东姚小青计划自公告披露之日起十五个交易日后的三个月内以集中竞价或 大宗交易方式减持公司股份不超过46,936,332股，占公司总股本比例1.5624%；高级管理人员陈瑞强计 划自公告披露之日起十五个交易日后的三个月内以集中竞价交易方式减持公司股份不超过169,000股， 占公司总股本比例0.0056%；高级管理人员张坤计划自公告披露之日 ...

Group 1 - The company, Hongri Pharmaceutical, primarily offers two types of products: traditional Chinese medicine formula granules and finished pharmaceuticals [1] - The traditional Chinese medicine formula granules require a doctor's prescription, while the finished pharmaceuticals include prescription drugs such as Xuebijing injection, Anruotai, Bopu Ning, and Bopu Ai [1]

Group 1 - The company, Hongri Pharmaceutical, reported that as of September 30, 2025, the number of shareholders is 96,308 [2]

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-059 天津红日药业股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1．本次股东大会无增加、变更、否决提案的情况； 2．本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 天津红日药业股份有限公司（以下简称"公司"）董事会于2025年10月29日 以公告方式向全体股东发出召开2025年第三次临时股东大会的通知。本次股东大 会采取现场投票和网络投票相结合的方式召开。其中，现场会议于2025年11月17 日下午14:30在天津市武清开发区创业总部基地B01号楼公司会议室召开；通过深 圳证券交易所系统进行网络投票的时间为2025年11月17日上午09:15至09:25、 09:30-11:30，下午13:00-15:00；通过深圳证券交易所互联网投票系统投票的具 体时间为2025年11月17日09:15至2025年11月17日15:00的任意时间。 出席本次会议的股东及股东代表共 576 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于天津红日药业股份有限公司 2025 年第三次临时股东大会的法律意见书 康达股会字【2025】第 0477 号 致：天津红日药业股份有限公司 北京市康达律师事务所（以下简称"本所"）接受天津红日药业股份有限 公司（以下简称"公司"）的委托，指派本所律师参加公司 2025 年第三次临时 股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券 ...

Core Points - The Shanghai Composite Index is at 4017.68 points, above the six-month moving average, with a slight decline of 0.29% [1] - A total trading volume of A-shares reached 15648.48 billion yuan today [1] - 113 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The top three stocks with the highest deviation rates from the six-month moving average are: - Electric Investment and Financing (9.07%) - Jie Rong Technology (7.54%) - Annie Shares (4.91%) [1] - Other stocks with smaller deviation rates that have just crossed the six-month line include: - Baoland, Zhongnong Lihua, and Subote [1] Trading Data - The trading performance of selected stocks includes: - Electric Investment and Financing: +9.94% with a turnover rate of 2.09% - Jie Rong Technology: +10.00% with a turnover rate of 8.20% - Annie Shares: +6.44% with a turnover rate of 18.47% [1] - Additional stocks with notable performance include: - Yahua Electronics: +6.29% - Zhonglu Shares: +7.08% - Jinlihua Electric: +4.81% [1]

Core Viewpoint - Hongri Pharmaceutical (300026) confirmed on November 13 that the company's control is stable and its production and operations are normal [1] Group 1 - The company reassured investors about the stability of its control [1] - The company stated that its production and operations are functioning normally [1]

Group 1 - Hongri Pharmaceutical's subsidiary, Beijing Chaosi Electronic Technology Co., Ltd., showcased multiple products at the 138th China Import and Export Fair (Canton Fair) from October 31 to November 4 [1]

Group 1: Company Acquisition - Shanghai Zhiyuan Hengyue Technology Partnership has completed the acquisition of shares in Shangwei New Materials, now holding 58.62% of the company, making it the controlling shareholder [1] - The acquisition price was set at 7.78 yuan per share, with the total number of shares tendered accounting for 33.6332% of the company's total equity [1] Group 2: Revenue Forecast Adjustment - BeiGene has updated its revenue forecast for 2025, now expecting it to be between 36.2 billion and 38.1 billion yuan, an increase from the previous estimate of 35.8 billion to 38.1 billion yuan [3] - The adjustment in revenue expectations is attributed to the leading position of Baiyueze in the U.S. market and its ongoing expansion in Europe and other key global markets [3] Group 3: Shareholder Reduction Plans - Shandong Heda's director plans to reduce holdings by up to 350,000 shares, representing 0.1017% of the total equity [5] - Huawai Technology's shareholder intends to reduce holdings by up to 5.2 million shares, accounting for 1.92% of the total equity [7] - Shenghong Co. plans for specific shareholders and executives to collectively reduce holdings by up to 8.7887 million shares, which is 2.8165% of the total equity [9] - High Alliance New Materials' executives plan to reduce holdings by up to 26,630 shares, representing 0.061% of the total equity [11] - New Light Pharmaceuticals' shareholder intends to reduce holdings by up to 4.8 million shares, which is 3% of the total equity [13] - Mengguli's shareholders plan to reduce holdings by up to 13.7885 million shares, accounting for 3% of the total equity [15] - Wanli Stone's general manager plans to reduce holdings by up to 3.7 million shares, representing 1.63% of the total equity [16] - Hongri Pharmaceuticals' shareholders and executives plan to reduce holdings by up to 47.3373 million shares, which is 1.58% of the total equity [17] - Feilihua's executives plan to reduce holdings by up to 620,000 shares, accounting for 0.1187% of the total equity [19] - Zhou Dazheng's senior management plans to reduce holdings by up to 126,600 shares, representing 0.0117% of the total equity [21] - Dali Cape's shareholder intends to reduce holdings by up to 18 million shares, which is 4.5% of the total equity [22] - Yixin Hall's actual controller plans to reduce holdings by up to 11.7121 million shares, accounting for 2% of the total equity [22] - Online and Offline's vice president plans to reduce holdings by up to 23,500 shares, representing 0.03% of the total equity [22] - Lige Optical's specific shareholder plans to reduce holdings by up to 930,400 shares, which is 0.7692% of the total equity [23] - Zhenhua Co.'s specific shareholder plans to reduce holdings by up to 930,400 shares, representing a significant deviation from the company's fundamentals [25] - Wenke Co.'s specific shareholder plans to reduce holdings by up to 3.5 million shares, accounting for 0.55% of the total equity [26] - Shanghai Hanxun's controlling shareholder plans to transfer 5% of the company's shares, totaling approximately 621 million yuan [27]